Initial Tx for 65 yo, int-2, sympt MF, baseline anemia? High-risk MF, anemia develops on Rux: Adjust dose?

Which treatment would you most likely initiate for a 65-year-old patient with intermediate-2 myelofibrosis, splenomegaly and significant disease-related symptomatology who has already received EPO and danazol:

Additional Commentary:

What is the role of iron chelation for patients with MF who have frequent transfusion requirements?

Additional Commentary:

How common is the occurrence of hydroxyurea-related leg ulcers?

Additional Commentary:

Is hydroxyurea considered leukemogenic?

Additional Commentary:

Is there cross-resistance between ruxolitinib and other JAK2 inhibitors?

Additional Faculty Comments:

• Cross-resistance between Rux and other JAK2 inhibitors?
• Is hydroxyurea considered leukemogenic?
• How common is the occurrence of hydroxyurea-related leg ulcers?
• Role of iron chelation for pts with MF and frequent transfusions?

OVERVIEW OF ACTIVITY

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses and other practitioners involved in the management of myelofibrosis.

Patterns of Care Data Regarding Ruxolitinib Use in Patients without JAK2 Mutations

Allotransplant in patients with MF?

In what situations, if any, do you recommend allotransplant to patients with MF?

Splenectomy in patients with MF?

Presently, how often do you recommend splenectomy to patients with MF?

Other diseases most commonly confused with MF?

Based on your clinical experience, which of the following disease states is most often confused with a diagnosis of myelofibrosis (MF)?

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses and other practitioners involved in the management of myelofibrosis.